FOLH1 and adrenal cortex carcinoma: Drawing on the experience of 177Lutetium (177Lu)–PSMA-617 in the treatment of metastatic castration resistant prostate cancer (mCRPC), this adds treatment possibilities for ACC and other SGCs.